Broad Institute Taps Complete Genomics to Further Cancer Biomarker Research
Complete Genomics will conduct complete human genome sequencing pilot studies of glioblastoma and melanoma for the Broad Institute. The company will sequence five genomes from samples provided by the institute.
The first genome sequenced will be a test case that has already been studied extensively by the scientific community. The other four genomes are tumor and matched-pair normals; one pair will be used to study glioblastoma and the other melanoma.